Aripiprazole

is prescribed to treat:

• Schizophrenia, bipolar disorder, and depression augmentation • Various related conditions in the mental health category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Aripiprazole (Abilify) is an atypical antipsychotic used for schizophrenia, for bipolar disorder, and as adjunctive treatment in major depressive disorder. It works through a mechanism distinct from every other agent in its class, and that difference explains both its favourable metabolic profile and its most characteristic side effect.

Mechanism of Action

Aripiprazole is a partial agonist at dopamine D2 receptors rather than an antagonist. A partial agonist produces submaximal activation: where dopamine activity is excessive it acts functionally as an antagonist by displacing full agonism, and where dopamine activity is low it provides some stimulation. This is often described as dopamine system stabilisation.

The practical consequences are distinctive. Because it does not fully block D2 receptors, aripiprazole causes considerably less prolactin elevation than risperidone — and in fact tends to lower prolactin, which makes it the usual switch target when hyperprolactinemia is the limiting problem. It is also less likely to produce the dysphoria and cognitive dulling associated with complete dopamine blockade.

Its metabolic profile is among the most favourable in the class, with less weight gain and less effect on glucose and lipids than olanzapine or quetiapine — though not none, and monitoring is still required.

Aripiprazole is also a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A, which contributes to its antidepressant augmentation effect and to its relatively low rate of extrapyramidal symptoms.

Akathisia

Akathisia is aripiprazole's signature adverse effect and is more common with it than with most other atypicals — a direct consequence of partial dopamine agonism.

It is an inner sense of restlessness, an inability to sit still, often described as needing to move or as crawling discomfort. It is genuinely distressing, and it is associated with treatment discontinuation and, in severe cases, with worsening of suicidal thinking.

The clinical trap is that akathisia is readily mistaken for worsening agitation, anxiety, or psychiatric deterioration. Interpreted that way, the natural response is to increase the dose — which makes it worse and confirms the misinterpretation. Recognising akathisia and reducing the dose, or adding a beta blocker such as propranolol, resolves it.

Patients should be told about it before starting so they can describe it accurately rather than reporting simply that they feel worse. Asking directly at follow-up — whether they feel restless, whether they can sit through a meal or a television programme — detects it more reliably than open questions do. Our psychiatric team manages these regimens, and the MedlinePlus aripiprazole entry covers prescribing detail.

Clinical Use

In schizophrenia and bipolar disorder, aripiprazole is a reasonable first-line atypical, particularly where metabolic risk or prolactin elevation is a concern.

As adjunctive treatment in depression it is used at low doses added to an antidepressant when response has been partial. This is an evidence-based strategy with a real effect size, and it is worth being explicit with patients that being prescribed an antipsychotic does not imply a psychotic illness — the framing matters, and unexplained prescription of an antipsychotic for depression causes understandable alarm and non-adherence.

A long-acting injectable formulation is available and is valuable where oral adherence is inconsistent — a common and consequential problem in schizophrenia, where each relapse carries functional cost that is not fully recovered.

Aripiprazole is metabolised by CYP2D6 and CYP3A4, so inhibitors of either raise levels and dose reduction is appropriate. Impulse control problems — pathological gambling, compulsive shopping, hypersexuality, binge eating — have been reported and are thought to relate to dopamine agonism. These are not volunteered spontaneously and should be asked about directly.

Monitoring and Follow-Up

Metabolic monitoring applies across the antipsychotic class even where the individual agent is favourable. Record weight and BMI at baseline and track them; check waist circumference, fasting glucose or hemoglobin A1c, and a lipid panel at baseline, at three months, and at least annually.

Movement examination should cover both akathisia and, over longer treatment, tardive dyskinesia — less frequent with aripiprazole than with high-potency agents but still possible, and potentially permanent if the drug is continued after it appears.

Blood pressure should be checked sitting and standing during titration given orthostatic hypotension. Prolactin is not routinely monitored, since aripiprazole tends to lower it.

Ask specifically about restlessness and about impulse control behaviours. Neither is reported unprompted, and both are reversible on dose reduction or discontinuation. The National Institute of Mental Health provides patient-level background.

Special Populations

Antipsychotics carry a boxed warning of increased mortality in elderly patients with dementia-related psychosis, and aripiprazole is not approved for that use. Where behavioural symptoms genuinely require medication after non-pharmacologic approaches have failed, the lowest dose for the shortest period with documented justification is the standard.

In older adults, start low given orthostatic hypotension and falls risk. Hepatic and renal impairment generally do not require adjustment, though CYP2D6 poor metabolisers reach higher levels and warrant dose reduction. In pregnancy it is used when the psychiatric indication warrants, since untreated severe mental illness carries substantial risk.

Cross-titration is the usual way to switch onto or off aripiprazole, rather than stopping one agent and starting another. Because it is a partial agonist, abruptly replacing a full antagonist with aripiprazole can produce a transient worsening as dopamine transmission shifts, which is sometimes misread as the new drug failing.

When to Contact Your Doctor

Seek emergency care for high fever with muscle rigidity, confusion, and autonomic instability, which suggests neuroleptic malignant syndrome.

Report inner restlessness or an inability to sit still — this is akathisia, it is common with aripiprazole, and it needs a dose reduction rather than an increase. Report uncontrollable movements of the face, tongue, or limbs.

Report any new gambling, spending, sexual, or eating behaviour that feels out of character or hard to control; this is a recognised effect and reverses on stopping. Report substantial weight gain, increased thirst, or increased urination. Report fainting or near-fainting.

To review your dose, address restlessness, or discuss whether aripiprazole is the right agent for you, contact us or schedule a visit.